Three types of arginine methylation exist in mammalian cells: monomethylarginine (MMA), asymmetric dimethylarginine (ADMA) and symmetric dimethylarginine (SDMA). Type I PRMTs ((CARM1, PRMT1, PRMT2, PRMT3, PRMT6, and PRMT8) catalyze ADMA, while type II PRMTs (e.g. PRMTs 5 and 7) catalyze SDMA. Type II PRMTs are found to be strongly implicated in diseases like cancer. For example, PRMT5 plays a role in the repression of certain tumor suppressor genes such as RB tumor suppressors while PRMT7 overexpression is observed in breast cancer
40 mM Tris-HCl, pH 8.0,
110 mM NaCl, 2.2 mM KCl, 80 ug/ml Flag
Peptide, and 20% Glycerol.
>6 months at -80°C.
1. Zhao Q. et al., J. Nat. Struct. Mol. Biol. 16 (3), 304-311 (2009).
2. Wang L et al., Mol. Cell. Biol. 28 (20), 6262-6277 (2008).
Application Reference(s):
1. Unique Features of Human Protein Arginine Methyltransferase 9 (PRMT9) and Its Substrate RNA Splicing Factor SF3B2 (2015)
2. Coronin 2A (CRN5) expression is associated with colorectal adenoma-adenocarcinoma sequence and oncogenic signalling (2015)
